Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

JAMA

Volumn 295, Issue 8, 2006, Pages 891-894

  Bright, Rick A ^a,b,c   Shay, David K ^a   Shu, Bo ^a   Cox, Nancy J ^a   Klimov, Alexander I ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NOVAVAX INC   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; AMANTADINE; AMINO ACID; ASPARAGINE; RIMANTADINE; SERINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOASSAY; CHILD; CORRELATION ANALYSIS; GENE MUTATION; HUMAN; INFLUENZA A; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; UNITED STATES; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

EID: 33644536465     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.8.joc60020     Document Type: Article

References (27)

1. Fox JP, Cooney MK, Hall CE, Foy HM. Influenza virus infections in Seattle families, 1975-1979, II: pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol. 1982;116:228-242.
2. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med. 1978;298:587-592.
3. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.
4. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580-584.
5. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am. 1987;1:459-478.
6. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol. 1993;67:5585-5594.
7. Oxford JS, Galbraith A. Anti influenza virus activity of amantadine. Viral Chemother. 1984;1:169-252.
8. Reuman PD, Bernstein DI, Keefer MC, Young EC, Sherwood JR, Schiff GM. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res. 1989;11:27-40.
9. Younkin SW, Betts RF, Roth FK, Douglas RG Jr. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother. 1983;23:577-582.
10. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol. 1988;62:1508-1512.
11. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother. 1986;18(suppl B):19-29.
12. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis. 2002;34:E23-E25.
13. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696-1702.
14. Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis. 1991;164:969-972.
15. Bright RA, Medina M-J, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175-1181.
16. Public Health Agency of Canada. Interim recommendation for use of amantadine for influenza. Available at: http://www.phac-aspc.gc.ca/media/ advisories_avis/2006/statment060115.html. Accessibility verified January 27, 2006.
17. Degelau J, Somani SK, Cooper SL, Guay DR, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med. 1992;152:390-392.
18. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998;26:1418-1424.
19. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 1992;176:119-130.
20. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother. 1991;35:1741-1747.
21. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Arch Intern Med. 1995;155:533-537.
22. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis. 2003;188:57-61.
23. Ziegler T, Hemphill ML, Ziegler ML, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis. 1999;180:935-939.
24. Bright RA, Shay D, Bresee J, Klimov A, Cox N, Ortiz J. High levels of adamantane resistance among influenza A(H3N2) viruses and interim guidelines for use of antiviral agents: United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2006;55:44-46.
25. Hurt AC, Barr IG, Durrant CJ, Shaw RP, Sjogren HM, Hampson AW. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Commun Dis Intell. 2003;27:542-547.
26. Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 2004;62:37-45.
27. Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res. 2004;103:195-197.